Evidence map›Paper›PMID 41023138›Full record

ArticleCommunications chemistry2025

MolGraph-xLSTM as a graph-based dual-level xLSTM framework for enhanced molecular representation and interpretability.

Yan Sun, Yutong Lu, Yan Yi Li, Zihao Jing, Carson K Leung, Pingzhao Hu

Abstract read
In one paragraph

Article in Communications chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yan SunDepartment of Computer Science, University of Manitoba, Winnipeg, MB, Canada.
Yutong LuBiostatistics Division, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
Yan Yi LiBiostatistics Division, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0009-0004-9174-1396
Zihao JingDepartment of Computer Science, Western University, London, ON, Canada.
Carson K LeungDepartment of Computer Science, University of Manitoba, Winnipeg, MB, Canada.ORCID http://orcid.org/0000-0002-7541-9127
Pingzhao HuDepartment of Computer Science, University of Manitoba, Winnipeg, MB, Canada. phu49@uwo.ca.ORCID http://orcid.org/0000-0002-9546-2245

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Predicting molecular properties is essential for drug discovery, and computational methods can greatly enhance this process. Molecular graphs have become a focus for representation learning, with Graph Neural Networks (GNNs) widely used. However, GNNs often struggle with capturing long-range dependencies. To address this, we propose MolGraph-xLSTM, a novel graph-based xLSTM model that enhances feature extraction and effectively models molecule long-range interactions. Our approach processes molecular graphs at two scales: atom-level and motif-level. For atom-level graphs, a GNN-based xLSTM framework with jumping knowledge extracts local features and aggregates multilayer information to capture both local and global patterns effectively. Motif-level graphs provide complementary structural information for a broader molecular view. Embeddings from both scales are refined via a multi-head mixture of experts (MHMoE), further enhancing expressiveness and performance. We validate MolGraph-xLSTM on 21 datasets from the MoleculeNet and Therapeutics Data Commons (TDC) benchmarks, covering both classification and regression tasks. On the MoleculeNet benchmark, our model achieves an average AUROC improvement of 3.18% for classification tasks and an RMSE reduction of 3.83% for regression tasks compared to baseline methods. On the TDC benchmark, MolGraph-xLSTM improves AUROC by 2.56%, while reducing RMSE by 3.71% on average. These results confirm the effectiveness of our model in learning generalizable molecular representations for drug discovery.

Identifiers

PMID41023138
PMCPMC12480901

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.